“Advancements in Peptide API Manufacturing & Outsourcing Trends”
- A prominent trend in peptide API manufacturing is the increasing adoption of advanced synthesis technologies, such as solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and microwave-assisted techniques. These innovations enhance production efficiency, reduce costs, and enable the synthesis of complex peptide structures, thereby improving scalability and quality control
- The growing demand for GLP-1 receptor agonists, driven by the rising prevalence of type 2 diabetes and obesity, is significantly impacting the peptide API market. Pharmaceutical companies are investing heavily in expanding manufacturing capacities to meet this demand
- For instance, Eli Lilly has committed an additional USD 5.3 billion to a new Indiana manufacturing site to boost production of its diabetes and weight loss drugs, Mounjaro and Zepbound
- Outsourcing peptide API manufacturing to Contract Manufacturing Organizations (CMOs) is becoming increasingly prevalent, especially in regions such as Asia-Pacific. Countries such as India and China offer cost-effective production facilities, making them attractive destinations for pharmaceutical companies seeking to reduce expenses and enhance efficiency
- The integration of green chemistry and sustainable manufacturing processes is gaining traction in the peptide API industry. Companies are exploring environmentally friendly methods, including the use of recombinant DNA technology, to minimize chemical byproducts and reduce environmental impact
